Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 32

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 32
---
 of our arrangement with Keystone may also make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales. We may use proceeds from sales of our Common Stock made pursuant to the Keystone Purchase Agreements in ways with which you may not agree or in ways which may not yield a significant return. We will have broad discretion over the use of proceeds from sales of our Common Stock made pursuant to the Keystone Purchase Agreements, including for any of the purposes described in the section entitled “ Use of Proceeds,” and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds, their ultimate use may vary substantially from their currently intended use. While we expect to use the net proceeds from this offering as set forth in “ Use of Proceeds,” we are not obligated to do so. The failure by us to apply these funds effectively could harm our business, and the net proceeds may be used for corporate purposes that do not increase our operating results or enhance the value of our Common Stock. 11 Risks Related to this Offering by the Selling Securityholder The shares of Common Stock being offered in this prospectus represent a substantial percentage of the outstanding shares of Common Stock, and the sales of such shares, or the perception that these sales could occur, could cause the market price of the Common Stock to decline significantly. Under this prospectus, the Selling Securityholder can resell up to a total of 2,100,000 shares of Common Stock. The shares of Common Stock being offered for resale pursuant to this prospectus by the Selling Securityholder would represent approximately 8.2% of the shares of fully-diluted Common Stock outstanding as of May 19, 2025, assuming and after giving effect to the issuance of Common Stock upon exercise of all outstanding Preferred Warrants and the maximum number of shares of Common Stock issuable upon conversion of all outstanding Preferred Shares. Given the substantial number of shares of Common Stock being registered pursuant to this prospectus, the sale of such shares, or the perception in the market of the potential for the sale of a large number of shares, could increase the volatility of the market price of the Common Stock or result in a significant decline in the public trading price of the Common Stock. Sales of a substantial number of our securities in the public market by the Selling Securityholder and/or by